Bio-Rad Laboratories (FRA:BUWA) Tariff Resilience Score: 6/10 (As of Jul. 08, 2026)


FRA:BUWA Bio-Rad Laboratories Inc FRA:BUWA
72 GF Score
Price €256.00
GF Value €272.70
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Tariff Resilience Score?

Bio-Rad Laboratories FRA:BUWA -0.54% 72 Tariff Resilience Score is 6 as of Jul. 08, 2026. GuruFocus rates FRA:BUWA with a GF Score™ of 72/100 and a GF Value™ of €272.70 (Fairly Valued). The stock has 5 warning signs investors should review. Among 836 Medical Devices & Instruments companies, Bio-Rad Laboratories ranks better than 91.03% on this metric.

Bio-Rad Laboratories has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Bio-Rad Laboratories has Bio-Rad has a global supply chain with significant manufacturing in the US and Europe. It faces moderate exposure to tariffs, especially in China. However, it has diversified suppliers and can adjust pricing to mitigate impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Bio-Rad Laboratories might have Average Resilient.

Bio-Rad Laboratories  (FRA:BUWA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Bio-Rad Laboratories Tariff Resilience Score Related Terms

FRA:BUWA vs GKOS, BRKR, PODD: Tariff Resilience Score Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Rad Laboratories Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Tariff Resilience Score falls into.


FRA:BUWA
72GF Score
Bio-Rad Laboratories Inc FRA:BUWA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Bio-Rad Laboratories (FRA:BUWA) has a Tariff Resilience Score of 6 as of Jul. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Bio-Rad Laboratories ranks #75 out of 836 companies in the Medical Devices & Instruments industry, placing it in the top 9%.
Is Bio-Rad Laboratories' Tariff Resilience Score too high?
Bio-Rad Laboratories' current Tariff Resilience Score is 6. Based on the distribution chart, Bio-Rad Laboratories ranks #75 out of 836 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bio-Rad Laboratories has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Tariff Resilience Score compare to GKOS and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #75 out of 836 companies for Tariff Resilience Score. This places Bio-Rad Laboratories in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Bio-Rad Laboratories's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Fairly Valued. The stock's GF Value™ is €272.70, compared to a current price of €256.00 — trading 6.1% below its estimated fair value. The current Tariff Resilience Score is 6. Bio-Rad Laboratories' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Tariff Resilience Score is 6 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued. The current stock price of €256.00 is trading 6.1% below its estimated GF Value™ of €272.70. GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.

Key valuation signals for FRA:BUWA:

  • Tariff Resilience Score: 6
  • GF Value™: €272.70 vs. price of €256.00 (6.1% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Rad Laboratories Business Description

Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
72GF Score

Get the complete analysis for FRA:BUWA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€256.00
Price
€272.70
GF Value